Home > Result Summaries: Compounds > Combined Measles, Mumps, Rubella, Varicella Vaccine > Result Summary for 208136/041

Result Summary for 208136/041

Result Summary

Protocol ID:	208136/041
Clinical Study ID:	208136/041
Official Title:	Study to evaluate immunogenicity and safety of three production lots of GSK Bios’ combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children, as compared to separate administration of GSK Bios’ Priorix® and Varilrix® vaccines.
Phase:	phase 3
Study Indications or Diseases:	Measles, Mumps, Rubella, Varicella
Generic Name:	Combined Measles, Mumps, Rubella, Varicella Vaccine
Trade/Product Name:	Priorix-Tetra
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Zepp F et al. ANTIBODY PERSISTENCE AND VARICELLA BREAKTHROUGH CASE ASSESSMENT THREE YEARS AFTER ADMINISTRATION OF MEASLES-MUMPS- RUBELLA-VARICELLA (MMRV) VACCINE IN CHILDREN AGED 11-23 MONTHS. Abstract presented at the 26th Annual Meeting of the ESPID, Graz, Austria, 13-17 May 2008. Knuf M et al. (2011) Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Eur J Pediatr. [Epub ahead of print].